ZENTIVA, |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30 EUR | 0.00% |
|
0.00% | 0.00% |
| Sales 2017 | 143M 153M | Sales 2018 | 36.17M 38.82M | Capitalization | 405M 435M |
|---|---|---|---|---|---|
| Net income 2017 | 78M 83.71M | Net income 2018 | 2M 2.15M | EV / Sales 2017 | 3.97 x |
| Net cash position 2017 | 0.09 0.1 | Net cash position 2018 | 0.77 0.83 | EV / Sales 2018 | 11.2 x |
| P/E ratio 2017 |
7.27
x | P/E ratio 2018 |
177
x | Employees | 90 |
| Yield 2017 |
13.8% | Yield 2018 |
-
| Free-Float | 1.18% |
More Fundamentals
* Assessed data
1 month
30.00
30.00
Current year
30.0030.00
1 year
30.0030.00
3 years
11.0092.00
5 years
11.00270.00
10 years
11.00370.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 15-11-11 | |
| Corporate Officer/Principal | - | 22-08-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kenneth Lynard
BRD | Director/Board Member | 56 | 20-11-14 |
Mojmír Krutý
BRD | Director/Board Member | - | 13-07-07 |
Martin Albert
BRD | Director/Board Member | - | 18-10-17 |
Zentiva as is a Slovakia-based company engaged in generic pharmaceuticals business sector. The Company develops, manufactures, and sells generic medicinal products, primarily used in primary care sector. Its portfolio includes preparations for various therapeutic areas, including cardiovascular system, womenâs healthcare, respiratory system, antimicrobials, urological system, central nervous system, pain, and gastrointestinal system.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 52.07M | |
| +20.44% | 21.89B | |
| +13.49% | 14.45B | |
| +13.50% | 13.63B | |
| +38.22% | 11.49B | |
| -8.59% | 6.85B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.35% | 5.06B | |
| -5.36% | 4.66B |
- Stock Market
- Equities
- 1SKF401E Stock
